TG Therapeutics (TGTX) Q2 2026 Earnings Call Transcript

TG Therapeutics reported Q2 2026 U.S. BRIUMVI net product revenue of ~$227.7M (+64% YoY) and total global revenue of ~$240.3M, exceeding guidance; gross margin was ~87% (U.S.) and ~83% (company). Management raised full-year U.S. guidance to $890M–$905M (from prior projections) and expects ~ $950M global revenue for 2026, with a projected Q4 U.S. net revenue >$250M to reach a ~$1B annualized run rate. Operating income was $21.7M (net income $7.8M / $0.05 EPS), but would have been ~$76M operating income excluding ~$55M in nonrecurring subcutaneous/secondary-source manufacturing charges; Phase 3 ENHANCE topline data supported a single-600mg infusion initiation and subcutaneous Phase 3 timing is late 2026–early 2027.

Analysis

TG is starting to look less like a single-product commercial story and more like a self-funding platform with multiple shots on goal. The key market mechanism is not just faster revenue growth, but improving durability: more first-line starts and stickier persistence reduce dependence on costly switching incentives, which should support margins and valuation quality into 2027. That said, the current revenue base still matters more than the pipeline for the next 2-3 quarters, so the stock will trade primarily on whether growth keeps compounding without gross-to-net leakage or a step-up in SG&A.

Competitive dynamics are favorable but not one-way. The IV franchise is still taking share in a crowded anti-CD20 category, while the subcutaneous program is really an option on access to the self-administered segment and a hedge against route-of-administration preference shifts at Roche and Novartis. The second-order effect is that infusion-center economics matter less if TG can own both routes; that could pressure incumbents that rely on channel inertia more than clinical differentiation.

The main near-term risk is that consensus may be extrapolating the current run-rate too cleanly into 2027 before the subcu readout proves anything commercially meaningful. The falsifier is simple: if Q3 looks like true deceleration rather than seasonality, or if gross-to-net drifts above the mid-60s while DTC and manufacturing costs stay elevated, the multiple should compress. Conversely, if the company exits 2026 at a $1B annualized run rate and subcu data land on time, this can rerate well before any meaningful pipeline revenue exists.

Key Decisions for Investors

• Long TGTX on post-earnings pullbacks over the next 2-6 weeks; use any 5-8% drawdown to add, with the thesis invalidated if Q3 U.S. growth slows materially below management’s implied second-half trajectory.
• Buy a small 6-12 month TGTX call-spread position into the late-2026/early-2027 subcutaneous readout; the risk/reward is asymmetric if the formulation expands addressable market as planned, but size modestly because commercial uptake is unproven.
• Pair trade: long TGTX / short RHHBY or NVS as a hedge on anti-CD20 share loss; this expresses relative share transfer without betting on broad biotech beta, and should work if TG keeps winning both switch and naive starts.
• Set a hard risk alert on TGTX if gross-to-net moves above the mid-60s or if management signals DTC/manufacturing costs are rising faster than revenue leverage; that would cap 2027 earnings power and justify de-risking.
• If already long, hold through the next catalyst but trim into strength if the market starts valuing the subcu program as if it were already de-risked; commercial execution is real, but the pipeline optionality is still only optionality.